Navigation Links
Studies Show Effect of BYDUREON™ on A1C and Weight for Up to Three Years
Date:6/24/2011

eat diabetes and obesity. Amylin is headquartered in San Diego.

Through a long-standing commitment to diabetes care, Lilly provides patients with breakthrough treatments that enable them to live longer, healthier and fuller lives. Since 1923, Lilly has been the industry leader in pioneering therapies to help healthcare professionals improve the lives of people with diabetes, and research continues on innovative medicines to address the unmet needs of patients.

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes' robust pipeline includes extended-release injectable and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Waltham, Mass., Alkermes has a research facility in Massachusetts and a commercial manufacturing facility in Ohio.

This press release contains forward-looking statements about Amylin, Lilly and Alkermes. Actual results could differ materially from those discussed or implied in this press release due to a number of risks and uncertainties, including the risk that BYDUREON may not be approved by the FDA as soon as anticipated or at all; the companies' response to the FDA's complete response letter may not be submitted in a timely manner and/or the information provided in such response may not satisfy the FDA; the FDA may request additional information prior to approval; BYETTA and/or the approval of BYDUREON and the revenues generated from these produ
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.; Eli Lilly and Company; Alkermes, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Pearl Therapeutics Advances Its Long-Acting Bronchodilator Combination Product Candidate into Four Additional Phase 2 Studies
2. Best of ASCO Features Two Studies Led by US Oncology Research Affiliated Physicians
3. Data from Clinical Studies of bioTheranostics CancerTYPE ID® and Breast Cancer Index(SM) Molecular Diagnostic Tests Presented at ASCO 2011 Annual Meeting
4. Pharmacyclics Reports Recent Developments From Clinical Studies of its Btk Inhibitor PCI-32765
5. Genomic Health Presents Ten New Studies in Breast, Colon and Prostate Cancers at the American Society of Clinical Oncology (ASCO) Annual Meeting
6. Additional Data From Multiple Phase 1 and 2 Studies of S*BIOs Novel JAK2 Inhibitor SB1518 Demonstrate Safety and Efficacy for Treatment of Symptomatic Myelofibrosis (MF)
7. Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis
8. Genomic Health Announces Ten Studies Covering Breast, Colon and Prostate Cancers Accepted for Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting
9. Lilly Oncology to Unveil Data From More Than 30 Studies at ASCO
10. New Studies Support CardioFocus HeartLight™ Endoscopic Ablation Systems Notable Treatment Results for Paroxysmal Atrial Fibrillation
11. Esperion Announces Results From Phase 1 Study and Four Preclinical Studies for ETC-1002
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... BUENA, N.J., July 24, 2014  IGI Laboratories, Inc. (NYSE ... and manufacturing company, announced its financial results for the second ... Highlights , Total revenues of $6.5 million in ... the same quarter in 2013 , Total revenues of ... an increase of 78% over the same period in 2013 ...
(Date:7/24/2014)... , July 24, 2014  Alimera Sciences, Inc. ... that specializes in the research, development and commercialization of ... its second quarter of fiscal year 2014 financial results ... An investor conference call will follow on the same ... conference call will be hosted by Dan Myers ...
(Date:7/24/2014)...  Kinex Pharmaceuticals announced the receipt of an allowance ... for the commencement of a Phase I clinical study ... to be allowed by the US FDA in the ... orally active and highly selective inhibitor of Src tyrosine ... of p53, G2/M arrest of proliferating cell populations and ...
Breaking Medicine Technology:IGI Laboratories Announces Second Quarter 2014 Results 2IGI Laboratories Announces Second Quarter 2014 Results 3IGI Laboratories Announces Second Quarter 2014 Results 4IGI Laboratories Announces Second Quarter 2014 Results 5IGI Laboratories Announces Second Quarter 2014 Results 6IGI Laboratories Announces Second Quarter 2014 Results 7Alimera Sciences To Release Second Quarter 2014 Results 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4
... 5 Diplomat Specialty Pharmacy,announced today that their ... is now live and being utilized to manage,their ... eNAV(TM) as a,disease management tool for all disease ... Crohn,s Disease,and Chronic Kidney Disease., "Our current ...
... of Insulin Doses Administered Were Delivered Within Pre-Determined ... Guidelines and Standard Dosing Limitations, ... the dose accuracy of the SoloSTAR(R) disposable insulin pen,prefilled ... glulisine [rDNA origin] injection), found the pens,accurately delivered all ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System 2New Study Confirms Dose-Accuracy of SoloSTAR(R) Prefilled Insulin Pen 2
(Date:7/25/2014)... Agoura Hills dentist , Dr. Amir Choroomi, is ... is one of the most powerful whitening treatments available today, ... light-assisted treatment uses a prescription-strength gel that can penetrate quickly ... up stains that are in both the enamel and the ... and tobacco stains. , About Dr. Amir Choroomi, Expert ...
(Date:7/25/2014)... Health Advocate™, Inc., the nation’s leading ... West Corporation, is introducing its newest solution in an ... Enhance Quality. , The webinar will be held twice ... again at 2 PM ET. For more information or ... or call 866.799.2655. , In an environment of ...
(Date:7/25/2014)... quickly after Manchester research , Clinical judgement, combined ... arrival, is effective in reducing unnecessary hospital admissions ... findings of a research group in Manchester, published ... a huge difference to a large number of ... for emergency hospital admission. In Manchester, the incidence ...
(Date:7/25/2014)... prevents obesity could be on the horizon. Bacteria ... inhibit weight gain, insulin resistance and other adverse ... University investigators have discovered. , "Of course it,s ... senior investigator Sean Davies, Ph.D., assistant professor of ... negative consequences of obesity in mice, even though ...
(Date:7/25/2014)... York, New York (PRWEB) July 25, 2014 ... JDRF’s revenue and spending during fiscal year 2013 (July 1, ... National Institutes of Health (NIH), the JDRF is the largest ... It has global reach and relationships with most of ... positioned to deliver a cure for type 1 diabetes in ...
Breaking Medicine News(10 mins):Health News:Agoura Hills Dentist, Dr. Amir Choroomi, is Now Offering a Promotion on Zoom Whitening 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 2Health News:Health Advocate™, Inc., Holds Webinar to Introduce Provider-Centered Analytics 3Health News:Heart attack patients could be treated more quickly after Manchester research 2Health News:Vanderbilt study examines bacteria's ability to fight obesity 2Health News:Report: JDRF 2013 Annual Research Spending Down by $50 million 2
... to GSVM medical college in Kanpur remained affected today ... elite educational institutions entered the 11th day here. // ... the protest against Centre's decision to implement 27 per ... representatives of agitating doctors said., ,However, sources at ...
... a good way of relieving stress and providing the mind ... that exercise can lift a person's spirits// , and there ... clinical depression. Exercise helps in the reduction of anger, fatigue ... walking or running has become popular among health freaks. It ...
... some researchers found that milk chocolate containing caffeine has ... having better reaction times. ,Hence, chocolate ... others. ,Adding value to the above study, ... Professer, Dr. Bryan Raudenbush, Wheeling Jesuit University has done ...
... regulate breathing abnormalities of premature babies. Artificial breathing equipments ... with caffeine therapy and found to have a lower incidence ... , ,About 2,000 premature babies, who weighed below 1,250 grams, ... were studied. , ,More than 47 per ...
... direct talks with Prime Minister Manmohan Singh and decided to ... meeting with the medicos during which he told them that ... which would see a huge growth in the educational opportunities ... Prime Minister assured the medicos that they need not be ...
... A research conducted by the King’s Collage London, analysed health reports ... war in 2003 with those who took part// in the 1991 ... ,The study findings that are published in The Lancet ... War Syndrome" in British male armed forces personnel deployed to the ...
Cached Medicine News:
... non-adhesive sealing method maintains the ... (HALS) procedures, allowing the surgeon ... throughout. Because HALS requires incisions ... patients experience less trauma compared ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
... The SleepStyle 200 series offers ... integrated CPAP models. The design delivers ... patients. Performance features promote results in ... care. The strongest differentiator in the ...
... series offers a range of standard, ... design delivers therapy to meet the ... results in commercial and clinical effectiveness ... in the SleepStyle 200 series is ...
Medicine Products: